Aspire Biopharma gets Nasdaq extension to fix compliance issues and restructure, moving markets Dec. 15, 2025.

Acupuncture, real or sham, eased cognitive issues in breast cancer survivors, with real acupuncture showing lasting benefits.

Two Madrigal execs sold $24M in stock amid company's quarterly loss and delayed drug trial.

Over 300 global heart specialists trained in advanced complication management at a Chennai-based interventional course.

Crinetics begins Phase 3 trial for atumelnant, an oral drug targeting classic congenital adrenal hyperplasia by blocking ACTH receptors.

Terns Pharmaceuticals shares surged 53% on Dec. 14, 2025, after early trial results showed promising leukemia treatment results.

A new robotic biopsy system boosts lung cancer detection accuracy to 92% and enables same-day results, reducing anxiety and surgeries.

Protagenic Therapeutics reports positive Phase 1 results for PT00114, a potential treatment for rare genetic disorders, showing safety and biological activity.

A new dual-antibody therapy showed strong, lasting responses in patients with rare, hard-to-treat multiple myeloma.

Teva submits FDA application for monthly injectable schizophrenia treatment using Medincell's technology.